Oncology Outcomes

Oncology outcomes research tracks survival, treatment effects, and care quality for people with cancer.

Students meet cancer epidemiology and outcomes early; this cluster keeps claims tied to measured endpoints.

Claim ledger

What the evidence shows

Drawn from 4 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.

• ● Supporting studies only

  Multiple studies in this library examine oncology outcomes with empirical patient or population outcomes rather than opinion alone.

  3 studies
  1. 1ANXA1 in breast cancer prognosis
  2. 2Does socioeconomic status change cancer survival?
  3. 3Propofol vs sevoflurane and breast cancer survival

  Study comparison

  Study	Role	Design	N	Population	Outcome
  ANXA1 in breast cancer prognosis2015	Supports	CohortPooled BCAC tumour series plus familial BRCA cases; ANXA1 IHC associations	N=5752 · BCAC patients in primary analyses; plus familial BRCA cases in secondary analyses	Women with breast cancer in pooled BCAC cohorts (mostly non-BRCA carriers)	ANXA1 associations with tumour subtype markers and breast-cancer-specific survival
  Does socioeconomic status change cancer survival?2009	Supports	CohortNOWAC; education and household income vs cancer survival with stage and smoking adjustment	N=3849 · 3,849 incident invasive cancers with SES data from a 91,814-woman study population	Norwegian women with incident primary invasive cancer in NOWAC	Cancer survival by education and household income
  Propofol vs sevoflurane and breast cancer survival2023	Supports	RCT1:1 propofol vs sevoflurane for anaesthesia maintenance in curative primary breast cancer surgery	N=1670 · ITT: 841 propofol, 829 sevoflurane	Patients undergoing curative primary breast cancer surgery	5-year overall survival

• ○ Limited citations

  High-grade tumors had higher ANXA1 odds (OR adj 1.59); ANXA1 linked to basal-like/TN features; HER2+ ANXA1-overexpressing cases had worse 10-year BCSS (HR adj 1.70).

  1 study
  1. 1ANXA1 in breast cancer prognosis

• ○ Limited citations

  An overall negative SES–survival gradient was present. Stage contribution was inconsistent, smoking was important, and after adjusting for stage and smoking the education and income differences became non-significant.

  1 study
  1. 1Does socioeconomic status change cancer survival?

• ○ Limited citations

  Among 1670 patients analysed by intention to treat (841 propofol, 829 sevoflurane), five-year survival was about 92% in both arms, with a hazard ratio near 1 and no statistically significant difference. Results were similar after per-protocol analysis and adjustment for uneven triple-negative receptor status.

  1 study
  1. 1Propofol vs sevoflurane and breast cancer survival

• ○ Limited citations

  All unmarried groups had excess mortality vs married; for men, never-married excess mortality rose ~3.4 percentage points per decade, mainly among those diagnosed after age 70.

  1 study
  1. 1Marital status and cancer survival trends

Debates

Tensions and limits

Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.

Timeline

How understanding moved

Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.

Papers

4 studies in this library bear on Oncology Outcomes, ordered by citations.

• Marital status and cancer survival trends

  Among Norwegian cancer patients, never-married people—especially older men—showed growing excess mortality versus married peers over decades.

  BMC public health · 2011 · 54 citations

• ANXA1 in breast cancer prognosis

  ANXA1-positive breast tumors clustered with poor-prognosis features (high grade, basal/TN, BRCA1/2) and worse outcomes in some high-risk subgroups such as HER2+.

  BMC medicine · 2015 · 47 citations

• Does socioeconomic status change cancer survival?

  In Norwegian women, lower education and income predicted worse cancer survival until stage and smoking were accounted for.

  BMC public health · 2009 · 41 citations

• Propofol vs sevoflurane and breast cancer survival

  In the CAN randomised trial, five-year overall survival after primary breast cancer surgery was essentially the same with propofol or sevoflurane maintenance anaesthesia.

  EClinicalMedicine · 2023 · 37 citations

Questions

What is still open

1. Effect sizes and settings differ across oncology outcomes studies — digital vs clinic, trial vs observational — so results should not be pooled casually.

   Watch this

Ask PaperFren about Oncology Outcomes